Â鶹ŮÓÅ

Today, a nationwide shortage of the A.D.H.D. medications he relies on threatens his recovery. This drought of drugs like Adderall, Vyvanse and Ritalin — which has now stretched on for a year — is causing widespread suffering and increasing levels of disability among families across the United States. (Maia Szalavitz, 10/9)

We have become fluent in the new language of pharmacology, diabetes, and weight loss. Ozempic, Wegovy and Mounjaro are part of our public lexicon. Glucagon-like peptide-1 (GLP-1) receptor agonists are lifesaving drugs, created to help the hundreds of millions of people with Type 2 diabetes and clinical obesity. They promise to rid the United States of obesity, if our country can figure out how to make the pricey fix affordable. (Tressie McMillan Cottom, 10/9)

Earlier this year, Food and Drug Administration Commissioner Robert M. Califf proposed something radical: that private health care insurance companies (payers) should participate in clinical research on FDA-approved drugs. (Vijay Ramakrishnan, 10/6)